Web7 rows · Feb 20, 2014 · Brand name: Orbactiv. Generic name: oritavancin. Dosage form: Injection. Company: The Medicines Company. Treatment for: Skin and Structure Infection. … WebAug 7, 2014 · ORBACTIV approval is based on the results of the SOLO I and SOLO II clinical studies which were randomized, double-blind, multicenter trials that evaluated a single 1200 mg IV dose of ORBACTIV for ...
Dilution Oritavancin (Orbactiv™) - GlobalRPH
WebHow to use Orbactiv Vial This medication is given by a health care professional as a single dose. Depending on your product, this medication is injected slowly into a vein over 1 or 3 … WebIt works by preventing certain bacteria from making their own cell walls, thereby killing the bacteria. Tenkasi has been shown to work against bacteria (such as methicillin resistant … sharp australia printer drivers
Orbactiv Intravenous: Uses, Side Effects, Interactions
Web2.2 Preparation of ORBACTIV for Intravenous Infusion . ORBACTIV is intended for intravenous infusion, only after reconstitution and dilution. Three ORBACTIV 400 mg vials need to be reconstituted and diluted to prepare a single 1200 mg intravenous dose. Reconstitution: Aseptic technique should be used to reconstitute three ORBACTIV 400 mg … WebUse ORBACTIV in patients on chronic warfarin therapy only when the benefits can be expected to outweigh the risk of bleeding. Frequently monitor for signs of bleeding. [see Drug Interactions (7.1), Clinical Pharmacology (12.3)]. ORBACTIV has been shown to artificially prolong PT and for up to INR 24 hours, making the monitoring of Oritavancin, sold under the brand name Orbactiv among others, is a semisynthetic glycopeptide antibiotic medication for the treatment of serious Gram-positive bacterial infections. Its chemical structure as a lipoglycopeptide is similar to vancomycin. The U.S. Food and Drug Administration (FDA) and … See more Oritavancin shares certain properties with other members of the glycopeptide class of antibiotics, which includes vancomycin, the current standard of care for serious Gram-positive infections in the United States and Europe. It … See more Oritavancin is active against gram-positive aerobic bacteria such as enterococci, staphylococci, streptococci, and anaerobic bacteria such as Clostridium difficile , Clostridium perfringens See more Originally discovered and developed by Eli Lilly, oritavancin was acquired by InterMune in 2001 and then by Targanta Therapeutics in late 2005. In December 2008, the U.S. Food and Drug Administration (FDA) declined to approve oritavancin without … See more In 2003, results were presented from two pivotal phase-III clinical trials testing the efficacy of daily intravenous oritavancin for the treatment of acute bacterial skin and skin-structure infections See more • "Oritavancin". Drug Information Portal. U.S. National Library of Medicine. See more porcine ear